Melanoma management includes excision of the primary tumor and additional procedures that are 61 determined according to the stage. 1, 2 Subsequently, melanoma patients enter a follow-up period of 62 clinical, imaging and laboratory examinations, depending on the stage. Protocols for monitoring 63 melanoma patients vary among different centers. 3-6 64
The benefit of clinical periodic controls in melanoma patients is dual: First, the earliest 65 possible detection of loco-regional recurrence and, second, the earliest possible diagnosis of a 66 second primary melanoma (SPM) that will develop in a proportion of patients. 7 In the literature, the 67 percentage of melanoma patients that develop a SPM ranges between 2% and 20%. 8-16 68 Total body photography (TBP) and sequential digital dermatoscopic documentation (DDD) 69 are indicated for patients at high risk to develop melanoma. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Both techniques improve the 70 diagnostic performance of clinicians for melanoma diagnosis in terms of sensitivity and 71 specificity. 20 The number-needed-to excise (NNE), which reflects the ratio of malignant-to-benign 72 excised lesions, significantly improves when sequential imaging is used. 17, 18, 22, 24 It has also been 73 demonstrated that most melanomas diagnosed by TBP and DDD are either in situ or early 74 invasive. 25, 26 Although the precise indications for TBP and DDD are not based on robust evidence, 75 both methods are considered very useful for the surveillance of at least 2 groups of individuals: 76 patients with melanoma history, which carry the highest risk for a new melanoma, and individuals 77 with multiple atypical nevi. 27 
78
The primary aim of the present study was to investigate the prospective risk of SPM in a 79 cohort of melanoma patients. Secondary aims were to assess Secondary aims were to investigate 80 risk factors for SPM and to assess the usefulness of TBP and DDD in SPM detection. 81 82
Materials and Methods 83
This was a prospective observational study on a cohort of patients with melanoma history followed-84 up with TBP and DDD. The study was conducted in a tertiary hospital that is a referral center for 85 melanoma patients in Northern Greece. The enrolment started on 1 st January 2013 and the follow-up 86 of the patients is ongoing. The current analysis was conducted on September 2018 and included all 87 patients enrolled during the study period up to then. The ethics committee approval was waived, as 88 the study did not affect the routine diagnostic or therapeutic management of patients and was based 89 on secondary analysis of suitably anonymized datasets. 90
Patients with a recently diagnosed primary cutaneous melanoma of any stage were enrolled, 91 after having completed the treatment and staging procedure. At baseline, several factors associated 92 to the index melanoma and the patient's characteristics were assessed and recorded: sex; age; 93 reaction to sun exposure according to the Fitzpatrick phototype classification (I-V); familial 94 melanoma history; skin color with 3 possible values (fair, medium, dark); eye color with 3 possible 95 values (blue, gray/green/hazel, brown); hair color in young age with 3 possible values (blond/red, 96 brown/red-brown, black/dark brown); presence of more than 50 freckles; history of occupational 97 sun exposure; total nevus count as an absolute number (continuous variable), assessed by TBP and 98 DDD; location, Breslow thickness and stage of the index melanoma, using the 7 th edition of the 99 AJCC staging system for patients enrolled until 31/12/2017 and the 8 th edition for those enrolled 100 after 01/01/2018; use of systemic agents for metastatic melanoma. After the baseline visit, the 101 patients were scheduled for follow-up according to the standard protocol of our institution. The time 102 interval between follow-up visits was 4 months, except of patients with history of melanoma in situ 103 who were visited every 6 months. TBP and DDD were repeated at all follow-up visits and were 104 performed with the use of a commercially available digital device that includes a standardized 105 protocol for capturing clinical images. All the images (clinical and dermatoscopic) were captured 106 and evaluated by clinicians specialized in skin cancer diagnosis and management. All pigmented 107 lesions larger than 2mm in diameter were dermatoscopically documented, with the exception of 108 those that could be safely diagnosed as seborrheic keratosis, solar lentigo or dermatofibroma. The 109 dermatoscopic evaluation was based on the standardized melanoma-specific structures plus recently 110 described dermatoscopic predictors of melanoma in situ. 28,29 111 The primary endpoint of the current analysis was to calculate the annual and cumulative risk 112 of SPM within 5 years from the diagnosis of the index melanoma. Secondary endpoints were to 113 identify predictors of SPM associated either to the patient's phenotype or to characteristics of the 114 index melanoma, and to assess the usefulness of TBP and DDD for SPM detection. 
Epidemiologic data and characteristics of index melanomas 127
The cohort consisted of 977 melanoma patients that visited our department for the first follow-up 128 visit from the beginning of the study to the time of the analysis. Patients' data and the 129 characteristics of their index melanoma are shown in table 1. The mean age at baseline was 130 54.69±15.05 (range 15-89) years and the male-female ratio was 1.1:1. At baseline visit, the mean 131 time from the index melanoma diagnosis was 1.6 months, ranging from 1 to 4 months. The index 132 melanoma was invasive in 756 patients (77.4%) and in situ in 220 (22.6%). The mean Breslow 133 thickness of invasive melanomas was 1.92 ± 1.55mm (range 0.2mm-9.0mm). The stage of the index 134 melanoma at baseline was 0 in 220 patients (22.6%), IA in 143 (14.6%), IB in 182 (18.6%), IIA in 135 79 (8.1%), IIB in 76 (7.8%), IIC in 45 (4.6%), III in 113 (11.6%), and IV in 119 (12.2%) patients. 136
The mean nevus count was 32.6 (SD: 9.5, min: 1, max: 149). Concerning screening before the 137 diagnosis of the index melanoma, 13.4% of patients reported sequential visits yearly or every 2 138 years and 29.9% reported occasional visits. 139 Overall, 46 of 977 patients (4.7%) developed a SPM. Of them, 4 developed a third and 2 a fourth 158 primary melanoma within the study period, resulting in a total of 52 new primary melanomas in the 159 cohort. Analytic data concerning the time of appearance of SPM are shown in table 3. The annual 160 risk for a SPM was 2.46% within the first year, 1.61% for the second year, 1.43% for the third year, 161 1.43% for the fourth year and 1.17% for the fifth year of follow-up. Life table analysis showed that 162 the cumulative proportion of patients who did not developed a SPM in the 60-month period was 163 92.0%. Thus, the risk of developing a SPM within the first 5 years was 8.0% (figure 1). 164
The majority of new primary melanomas (35/52, 67.3%) were in situ and 17 (32.7%) were invasive. 165
The mean Breslow thickness of invasive SPM was 0.49mm, ranging from 0.2mm to 0.9mm. Of 52 166 melanomas, 6 (11.5%) were nevus-associated and 46 (88.5%) developed de novo. 167 168
Predictors of SPM 169
Our multivariate analysis revealed 3 potent predictors of SPM: nevus count, phototype and 170 occupational sun exposure (table 4 ). In detail, the hazard for developing a SPM was increased by 171 6% for each nevus added (HR=1.061, 95% CI: 1.039-1.084, p<0.001). The hazard risk for SPM was 172 reduced by 50% per each phototype level from I to IV. Finally, the history of occupational sun 173 exposure posed a 35-fold increased risk for SPM. All hazards were adjusted for the effect of The main finding of the present cohort study was that 4.7% of melanoma patients developed a SPM 208 within a period of 5 years and the 5-year cumulative risk was 8.0%. This finding justifies the 209 necessity of close clinical and dermatoscopic monitoring of melanoma patients at least for the first 5 210 years after diagnosis. Our results also suggest a higher annual risk during the first year (2.46%), 211 which becomes lower in the second (1.61%) and slightly but steadily decreases the following 4 212 years down to 1.17% during the 5 th year of monitoring (Table 3) measures. [8] [9] [10] [11] [12] [13] [14] [15] [16] The highest incidence of SPM was reported by Siskin and colleagues in Australia. 8 In 220 that study, the investigators re-contacted 1083 melanoma patients and reported that 20% of them 221 developed an additional primary melanoma. In studies conducted in the US, the reported percentage 222 of melanoma patients that develop a of SPM ranges between 7% and 12%. 9 -1 4 Studies in European 223 populations reported a lower rates of SPM. 15,16 Schuurman and colleagues analyzed the Dutch 224 cancer registry and reported a 5-year cumulative risk of 3.7% and a conditional cumulative risk for 225 the years 5 to 10 of 4.6% for SPM. 14 The variable rates of SPM in the literature might reflect 226 epidemiologic differences in melanoma incidence among populations, or might be attributed to 227 significantly different study designs and measures. For the same reasons, a direct comparison of the 228 rate of SPM found in our and previous studies is difficult. Our reported risk for SPM is higher than 229 previous studies in Europe and is rather comparable to risk rates reported in the US. This 230 discrepancy might be partially explained by the difference between a population-based study and an 231 institutional cohort study. It might be also attributed to the fact that our data derive from a 232 prospective close surveillance of melanoma patients, which increased the possibility of detection of 233 SPM and minimized the number of patients lost during follow up. Despite of the different reported 234 rates, all studies agree on a significant risk of SPM in patients with melanoma history. [8] [9] [10] [11] [12] [13] [14] [15] [16] 235 Several of the studies mentioned above investigated risk factors of SPM. 8, 11, 12, 14 Overall, 236 most of the known melanoma risk factors have been suggested also as predictors of SPM, with the 237 high total nevus count assessed as the strongest predictor. 8, 14 This is in absolute agreement with our 238 findings that suggest a 6.0% increase of the risk for SPM for every added nevus. Fair skin type, 239 inability to tan and a fair complex have also been proposed as risk factors for SPM. 8, 11, 12, 14 In our 240 cohort, each phototype level (from I to V) added a 50.0% risk for SPM. Finally, we found 241 occupational sun exposure to be associated with a significantly higher risk of SPM, which is 242 consistent to a previous study. 14 Although stratifying melanoma patients according to the risk of a 243 SPM remains of great research interest, we suggest that all melanoma patients should be closely 244 monitored, since they all carry a significant risk for SPM. 245
Our study also highlights the usefulness of TBP and sequential DDD as integral parts of 246 follow-up visits of patients with melanoma history. Of all new melanomas, 67.3% were in situ, and 247 the remaining 32.7% were thinner than 1mm, suggesting a high efficacy of the applied monitoring 248 protocol in early SPM diagnosis. Furthermore, the NNE for melanoma diagnosis was 1:1.3, 249 suggesting a high positive predictive value of the used diagnostic techniques. Of 52 SPM, 48.1% 250 were detected by TBP, which highlights the high value of clinical photography in detecting new 251 lesions. The mean age of patients with SPM diagnosed by TBP was higher as compared to those 252 diagnosed at baseline or by DDD. This finding suggests that the interpretation of a newly-appearing 253 lesion largely depends on the age, since the probability of a new lesion to be a melanoma increases 254 with age and the probability of nevus decreases accordingly. Another 34.6% of SPM were 255 diagnosed by sequential DDD. The latter finding highlights that some melanomas are diagnosed 256 only by dermatoscopic changes during follow up, without developing melanoma-specific 257 dermatoscopic criteria. This observation has been previously described and it is considered to 258 justify the photographic documentation of a large proportion of each patient's moles, even those 259 that do not display dermatoscopic atypia. 30 Although our data suggest a high efficacy of TBP and 260 DDD in detecting SPM in patients with melanoma history, this conclusion cannot be extrapolated to 261 other categories of individuals, such as those with multiple nevi. The sensitivity and specificity of 262 TBP and DDD in other groups needs to be assessed in appropriately designed studies and adjusted 263 to the time cost. 264
In our cohort, the longest period required to dermatoscopically monitor a featureless 265 melanoma in order to recognize it was 16 months. This finding is reasonable, since a melanoma is 266 very unlikely to remain dermatoscopically stable for a very long period. Although we cannot 267 exclude that in a larger cohort this time could be prolonged, the data from the current cohort suggest 268 that a lesion that remains stable at DDD for a long period (16 or 24 months) does not require further 269 dermatoscopic documentation. This could reduce the time required for the sequential visits and 270 improve the applicability of the monitoring strategy. 271
The main strength of our study was the prospective cohort design that allowed a time-to-272 event analysis. The main limitation was that all included patients followed the same monitoring 273 protocol, which did not allow an assessment of the optimal intervals between sequential visits. 274
Another limitation is associated to the possible diagnostic bias induced by the use sequential 275 dermatoscopic images that could force pathologists to diagnose as melanomas in situ lesions that 276 might have been otherwise classified as atypical/dysplastic nevi. 277
In conclusion, our study revealed an 8. Capsule summary
• The risk of second primary melanoma has only been assessed in retrospective studies. Our time-to-event analysis revealed a 5-year cumulative risk of 8.0%
for second primary melanoma. Individuals with a high nevus count, fair phototype and history of occupational exposure are at higher risk. Most melanomas were diagnosed by total body photography or by sequential dermatoscopic imaging. The number-needed to excise was 1:1.3.
• Patients with melanoma history are at high risk to develop a SPM and should be closely monitored with the use of total body photography and digital dermatoscopic imaging.
